Match tier
Listed
Presence
Current · Arkansas
Last published
2020
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
J
Junshuang Yang
Role not yet determined Is this you? Add your title
Also affiliated: United States Food and Drug Administration (2019–2020)
3 h-index
10 pubs
157 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
Metrics
- h-index: 3
- Publications: 10
- Citations: 157
Selected Publications
-
FDALabel for drug repurposing studies and beyond (2020)
-
Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine (2020)
-
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA (2019)
Collaboration Network
Top Collaborators
Taylor Ingle
National Center for Toxicological Research
3 shared publications
In database
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
- FDALabel for drug repurposing studies and beyond
Shraddha Thakkar
National Center for Toxicological Research (US)
3 shared publications
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
- FDALabel for drug repurposing studies and beyond
Joshua Xu
National Center for Toxicological Research
3 shared publications
In database
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
- FDALabel for drug repurposing studies and beyond
Weida Tong
National Center for Toxicological Research
3 shared publications
In database
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
- FDALabel for drug repurposing studies and beyond
Hong Fang
National Center for Toxicological Research
3 shared publications
In database
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
- FDALabel for drug repurposing studies and beyond
Leihong Wu
National Center for Toxicological Research
2 shared publications
In database
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
Zhichao Liu
National Center for Toxicological Research (US)
2 shared publications
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
Stephen Harris
National Center for Toxicological Research (US)
2 shared publications
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- FDALabel for drug repurposing studies and beyond
Guangxu Zhou
National Center for Toxicological Research (US)
2 shared publications
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
Darshan Mehta
National Center for Toxicological Research
2 shared publications
In database
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
Lawrence J. Lesko
University of Florida (US)
2 shared publications
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
- FDALabel for drug repurposing studies and beyond
Anna Zhao-Wong
1 shared publication
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Weigong Ge
National Center for Toxicological Research
1 shared publication
In database
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Ryley Uber
Pittsburg State University (US)
1 shared publication
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
Catherine Li
United States Food and Drug Administration (US)
1 shared publication
- Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine